346 related articles for article (PubMed ID: 12664551)
1. [Investigation of the activity of the preparation cerbiden against Candida spp].
Hladun NP; Bondarenko AS; Nahorna SS; Smyrnova OV
Mikrobiol Z; 2002; 64(6):57-61. PubMed ID: 12664551
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activity of phenylheptatriyne from Bidens cernua L. against yeasts.
Rybalchenko NP; Prykhodko VA; Nagorna SS; Volynets NN; Ostapchuk AN; Klochko VV; Rybalchenko TV; Avdeeva LV
Fitoterapia; 2010 Jul; 81(5):336-8. PubMed ID: 19837144
[TBL] [Abstract][Full Text] [Related]
3. [Study of the cerbiden spectrum of antifungal activity against fungi pathogenic to humans].
Smirnov VV; Hladun NP; Bondarenko AS; Hahorna SS; Zakharchenko VO
Mikrobiol Z; 2003; 65(3):70-7. PubMed ID: 12945196
[TBL] [Abstract][Full Text] [Related]
4. [Antifungal activity of the components of the drug cerbiden of plant origin].
Smirnov VV; Bondarenko AS; Gladun NP
Mikrobiol Z; 2003; 65(4):17-22. PubMed ID: 14618782
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal sensitivity of fluconazole, clotrimazole and nystatin against vaginal candidiasis in females of childbearing age.
Khan F; Baqai R
J Ayub Med Coll Abbottabad; 2010; 22(4):197-200. PubMed ID: 22455297
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of clotrimazole for Candida strains isolated from recent patient samples.
Schmidt A
Arzneimittelforschung; 1995 Dec; 45(12):1338-40. PubMed ID: 8595097
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
8. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility and resistance of Candida spp. to hamycin.
Athar MA
Sabouraudia; 1971 Nov; 9(3):256-62. PubMed ID: 4944203
[No Abstract] [Full Text] [Related]
10. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
11. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
Jandourek A; Brown P; Vazquez JA
Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
[No Abstract] [Full Text] [Related]
12. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Yang YL; Li SY; Cheng HH; Lo HJ;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
14. EUCAST technical note on Amphotericin B.
Lass-Flörl C; Arendrup MC; Rodriguez-Tudela JL; Cuenca-Estrella M; Donnelly P; Hope W;
Clin Microbiol Infect; 2011 Dec; 17(12):E27-9. PubMed ID: 22011310
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
17. [In vitro susceptibility of vaginal isolates of Candida vs clotrimazole and nystatin].
Suárez VL; Fernández Andreu CM
Rev Cubana Med Trop; 2003; 55(3):138-45. PubMed ID: 15849917
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of 6 antifungal agents on candida species isolated as causative agents from vaginal and other clinical specimens.
Ellabib MS; ElJariny IA
Saudi Med J; 2001 Oct; 22(10):860-3. PubMed ID: 11744942
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species.
Pfaller MA; Boyken L; Messer SA; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2004 Nov; 42(11):4977-9. PubMed ID: 15528683
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents.
Choukri F; Benderdouche M; Sednaoui P
J Mycol Med; 2014 Dec; 24(4):303-7. PubMed ID: 25442913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
